-
What’s the Deal with GLP-1 Microdosing?
Is Less Really More? When it comes to GLP-1 medications like Ozempic and Wegovy, that’s the question more providers and patients are starting to ask. Originally approved for type 2 diabetes and later for obesity treatment, GLP-1 and other incretin-based therapies have rapidly gained traction in both clinical and consumer spaces. If you’re newer to prescribing or supporting GLP-1 therapy, I’ve put together a four-part series covering key considerations, including initiation, weight management, cost, and side effect mitigation. Now, a new conversation is emerging: GLP-1 microdosing. What does microdosing mean in this context? Does it have clinical merit? And who…
-
ADA Scientific Sessions: Expanding the Discussion to Include Weight Bias
This past weekend, I had the pleasure of attending the American Diabetes Association’s 85th Scientific Sessions in Chicago. It was a phenomenal gathering of researchers, clinicians, scientists, and experts in the field of cardiometabolic health. One of the most compelling shifts I observed was the growing emphasis on obesity care and treatment. The Obesity Association, a new division of the American Diabetes Association, recently published the Standards of Care in Overweight and Obesity to guide respectful, evidence-based treatment. These standards highlight weight stigma and bias as critical issues in clinical practice. To support the launch of the standards, a special…
-
GLP-1 Success Starts with Dietitian Leadership
It should come as no surprise that a large part of the success with incretin-based therapies— like Ozempic, Wegovy, Mounjaro, and Zepbound—stems from the effective integration of lifestyle modifications, particularly nutrition. This success occurs at both the individual and programmatic levels. But it’s not always for the reasons you might expect. By the time most people begin incretin-based therapy, especially for weight management, they’ve often already tried a range of diets: calorie counting, commercial weight loss programs like Jenny Craig or Weight Watchers, and more. This time, they’re looking for something different—something that addresses the deeper pathophysiology and root causes…
